VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
IDXX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
IDXXIDEXX Laboratories, Inc.
$551.50$43.8B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksIDXXFinancials

IDEXX Laboratories, Inc. (IDXX) Financials

30Y historyFree accessUpdated daily

The company has successfully scaled operating income to $362.6 million in 2026Q1, maintaining gross margins above 60% throughout the last ten quarters.

IDXX Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue4.45B4.3B3.9B3.66B3.37B3.22B2.71B2.41B2.21B1.97B1.78B1.6B1.49B1.38B1.29B1.22B1.1B1.03B1.02B922.55M739.12M638.1M549.18M475.99M412.67M386.08M367.43M356.2M319.9M263M267.7M
Revenue Growth %13.08%10.42%6.46%8.72%4.73%18.79%12.45%8.75%12.4%10.91%10.83%7.81%7.9%6.47%6.13%10.45%6.96%0.74%11%24.82%15.83%16.19%15.38%15.34%6.89%5.08%3.15%11.35%21.63%-1.76%41.94%
Cost of Goods Sold1.69B1.64B1.52B1.47B1.36B1.33B1.14B1.04B971.7M871.68M799.99M711.62M669.69M620.94M594.19M572.18M524.77M505.35M494.26M459.03M359.59M315.19M270.16M245.69M219.94M202.75M170.78M164.9M142.2M119.8M102.9M
COGS % of Revenue-38.2%38.96%40.18%40.48%41.24%41.96%43.27%43.9%44.27%45.06%44.42%45.07%45.09%45.94%46.95%47.56%48.99%48.27%49.76%48.65%49.4%49.19%51.62%53.3%52.51%46.48%46.29%44.45%45.55%38.44%
Gross Profit2.76B2.66B2.38B2.19B2B1.89B1.57B1.37B1.24B1.1B975.44M890.27M816.12M756.12M699.15M646.51M578.62M526.28M529.77M463.52M379.53M322.9M279.02M230.3M192.72M183.33M196.66M191.3M177.7M143.2M164.8M
Gross Margin %62.05%61.8%61.04%59.82%59.52%58.76%58.04%56.73%56.1%55.73%54.94%55.58%54.93%54.91%54.06%53.05%52.44%51.01%51.73%50.24%51.35%50.6%50.81%48.38%46.7%47.49%53.52%53.71%55.55%54.45%61.56%
Gross Profit Growth %-11.8%8.63%9.26%6.08%20.27%15.05%9.99%13.14%12.5%9.57%9.09%7.94%8.15%8.14%11.73%9.95%-0.66%14.29%22.13%17.54%15.73%21.15%19.5%5.12%-6.78%2.8%7.65%24.09%-13.11%45.33%
Operating Expenses1.35B1.3B1.25B1.09B1.11B957.4M876.52M812.7M750.21M684.35M625.2M582.15M555.86M489.36M436.58M410.28M374.74M350.31M357.31M327.34M251.6M207.57M170.98M149.92M126.91M126.78M143.41M144.5M148.6M147.6M117.8M
OpEx % of Revenue-30.2%32.09%29.85%32.83%29.78%32.38%33.77%33.9%34.76%35.21%36.34%37.41%35.54%33.76%33.67%33.96%33.96%34.89%35.48%34.04%32.53%31.13%31.5%30.75%32.84%39.03%40.57%46.45%56.12%44%
Selling, General & Admin1.09B1.05B1.03B901.89M850.75M796.39M735.27M679.51M632.34M575.17M524.08M482.46M457.6M401.35M354.57M334.24M306.14M285.19M285.28M260M197.98M166.62M135.58M117.6M97.58M98.35M95.63M100M111.2M116.1M95.2M
SG&A % of Revenue-24.36%26.45%24.64%25.26%24.77%27.17%28.23%28.57%29.21%29.52%30.12%30.8%29.15%27.42%27.43%27.75%27.64%27.86%28.18%26.79%26.11%24.69%24.71%23.65%25.47%26.03%28.07%34.76%44.14%35.56%
Research & Development257.93M251.21M219.79M190.95M254.82M161.01M141.25M133.19M117.86M109.18M101.12M99.68M98.26M88M82.01M76.04M68.6M65.12M70.55M67.34M53.62M40.95M35.4M32.32M29.33M28.43M28.29M27.3M21.5M17.1M12.2M
R&D % of Revenue-5.84%5.64%5.22%7.57%5.01%5.22%5.53%5.33%5.54%5.7%6.22%6.61%6.39%6.34%6.24%6.22%6.31%6.89%7.3%7.25%6.42%6.45%6.79%7.11%7.36%7.7%7.66%6.72%6.5%4.56%
Other Operating Expenses00002.2M1.46M0000000000000000000000000
Operating Income1.41B1.36B1.13B1.1B898.76M932.03M694.52M552.85M491.33M413.03M350.24M299.91M260.25M266.76M262.56M236.22M203.88M175.97M172.46M136.18M127.93M115.33M108.03M80.39M65.81M56.55M53.25M46.8M29.1M-4.4M47M
Operating Margin %31.63%31.6%28.95%29.97%26.69%28.99%25.66%22.97%22.2%20.98%19.73%18.72%17.52%19.37%20.3%19.38%18.48%17.06%16.84%14.76%17.31%18.07%19.67%16.89%15.95%14.65%14.49%13.14%9.1%-1.67%17.56%
Operating Income Growth %-20.53%2.84%22.07%-3.57%34.2%25.63%12.52%18.96%17.93%16.78%15.24%-2.44%1.6%11.15%15.86%15.86%2.04%26.64%6.45%10.93%6.75%34.39%22.14%16.38%6.2%13.78%60.82%761.36%-109.36%42.86%
EBITDA1.52B1.47B1.26B1.21B1.01B1.04B790.52M640.86M574.51M496.17M428.46M368.87M319.14M321.36M314.97M284.43M249.84M225.74M221.28M177.28M157.75M139.7M126.46M99.28M85.94M78.78M72.73M64M45M10M57.4M
EBITDA Margin %34.12%34.08%32.28%33.11%30.01%32.24%29.21%26.63%25.96%25.2%24.13%23.03%21.48%23.34%24.35%23.34%22.64%21.88%21.61%19.22%21.34%21.89%23.03%20.86%20.83%20.41%19.79%17.97%14.07%3.8%21.44%
EBITDA Growth %18.53%16.55%3.81%19.92%-2.5%31.13%23.35%11.55%15.79%15.8%16.15%15.58%-0.69%2.03%10.74%13.84%10.67%2.02%24.81%12.38%12.92%10.47%27.37%15.53%9.09%8.32%13.64%42.22%350%-82.58%48.7%
D&A (Non-Cash Add-back)111.12M106.46M129.94M114.91M111.9M104.6M96M88.01M83.18M83.14M78.22M68.96M58.89M54.6M52.41M48.2M45.96M49.77M48.82M41.1M29.82M24.37M18.43M18.9M20.12M22.23M19.48M17.2M15.9M14.4M10.4M
EBIT1.41B1.36B1.14B1.1B899.83M932.46M695.11M553.27M492.49M418.28M353.89M302.38M261.98M268.65M264.46M237.97M204.54M176.46M174.78M136.18M127.93M115.33M108.03M80.39M65.81M56.55M53.25M46.8M29.2M-4.4M47M
Net Interest Income-37.84M-35.84M-18.51M-35.95M-38.79M-29.37M-32.54M-30.63M-33.59M-31.97M-28.39M-26.77M-13.7M-3.5M-1.95M-1.8M-1.75M-1.43M-2.27M000000000000
Interest Income1.79M2.42M12.7M5.63M1.06M434K586K427K1.15M5.25M3.66M2.47M1.73M1.89M1.9M0002.32M003.14M3.07M2.87M0000000
Interest Expense39.64M38.27M31.2M41.58M39.86M29.81M33.13M31.05M34.74M37.23M32.05M29.24M15.43M5.39M3.85M1.8M1.75M1.43M4.59M000000000000
Other Income/Expense-36.54M-35.84M-18.51M-35.95M-38.79M-29.37M-32.54M-30.63M-33.59M-31.97M-28.39M-26.77M-13.7M-3.5M-1.95M-1.8M-1.75M-1.43M-2.27M-1.34M2.82M3.14M3.07M2.87M2.96M2.23M5M5.8M-30.4M-27.8M8.3M
Pretax Income1.37B1.32B1.11B1.06B859.97M902.65M661.99M522.22M457.74M381.06M321.85M273.14M246.56M263.26M260.62M234.42M202.13M174.54M170.19M134.84M130.75M118.47M111.1M83.25M68.77M58.78M58.25M52.6M-1.2M-32.2M55.3M
Pretax Margin %30.8%30.77%28.48%28.99%25.54%28.07%24.46%21.7%20.68%19.35%18.13%17.05%16.59%19.12%20.15%19.24%18.32%16.92%16.62%14.62%17.69%18.57%20.23%17.49%16.66%15.22%15.85%14.77%-0.38%-12.24%20.66%
Income Tax274.31M264.73M221.96M216.13M180.88M157.81M79.85M94.43M80.69M117.79M99.79M81.01M64.6M75.47M82.33M72.67M60.81M52.3M54.02M40.83M37.22M40.67M33.16M26.28M23.38M21.16M21.61M20M14M-11.1M22.7M
Effective Tax Rate %20.03%19.99%20%20.37%21.03%17.48%12.06%18.08%17.63%30.91%31.01%29.66%26.2%28.67%31.59%31%30.08%29.97%31.74%30.28%28.47%34.33%29.85%31.56%34%36%37.11%38.02%-1166.67%34.47%41.05%
Net Income1.1B1.06B887.87M845.04M679.09M744.85M581.78M427.72M377.03M263.14M222.04M192.08M181.91M187.8M178.27M161.79M141.28M122.22M116.17M94.01M93.68M78.25M78.33M57.09M45.39M37.62M36.63M32.6M-15.2M-21.1M32.6M
Net Margin %24.63%24.62%22.78%23.08%20.17%23.17%21.49%17.77%17.04%13.36%12.51%11.99%12.24%13.64%13.78%13.28%12.8%11.85%11.34%10.19%12.67%12.26%14.26%11.99%11%9.74%9.97%9.15%-4.75%-8.02%12.18%
Net Income Growth %22.38%19.33%5.07%24.44%-8.83%28.03%36.02%13.44%43.28%18.51%15.6%5.59%-3.14%5.35%10.19%14.51%15.59%5.21%23.57%0.36%19.71%-0.1%37.21%25.78%20.65%2.7%12.37%314.47%27.96%-164.72%51.63%
Net Income (Continuing)1.1B1.06B887.87M845.04M679.09M744.84M582.13M427.79M377.05M263.27M222.05M192.13M181.95M187.79M178.29M161.75M141.32M122.23M116.17M94.01M93.68M78.25M77.94M57.09M45.39M37.62M36.63M32.6M-15.2M-21.1M32.6M
Discontinued Operations0000000000000000000000000000000
Minority Interest000000707K352K280K264K139K130K73K28K34K14K46K10K000300K000000000
EPS (Diluted)13.5813.0810.6710.068.038.606.714.894.262.942.442.051.791.741.591.391.191.000.940.730.710.570.550.400.330.270.260.21-0.10-0.140.21
EPS Growth %25.32%22.59%6.06%25.28%-6.63%28.17%37.22%14.79%44.9%20.49%19.02%14.53%2.87%9.43%14.39%16.81%19%6.38%28.77%2.82%24.56%3.64%37.5%21.21%22.22%3.85%23.81%310%28.57%-166.67%40%
EPS (Basic)-13.1710.7710.178.128.746.824.974.343.002.472.071.821.771.621.431.231.040.970.770.750.600.570.420.340.280.270.21-0.10-0.140.22
Diluted Shares Outstanding80.67M80.67M83.25M83.98M84.6M86.57M86.72M87.54M88.47M89.57M90.88M93.65M101.5M107.97M112.31M116.43M119.12M121.36M124.5M128.91M131.81M136.22M143.2M143.72M140.17M138.56M144.32M159.02M152M150.71M157.11M
Basic Shares Outstanding80.1M80.1M82.47M83.07M83.62M85.2M85.34M86.11M86.86M87.77M89.73M92.6M100.09M106.32M109.97M113.58M115.43M117.62M119.91M123.12M125.73M130.08M136.86M137.08M134.49M133.17M138.3M153.41M152M150.71M148.18M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrong
Balance SheetHealthy
Cash FlowRobust
Top Statement Risk

Veterinary labor supply constraints

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Momentum Accelerates Significantly

As reported in recent financial filings, IDEXX has demonstrated a clear acceleration in top-line performance, with revenue growth climbing from 3.6% in 2025Q1 to 14.3% by 2026Q1, suggesting robust demand for diagnostic consumables and services despite broader macroeconomic headwinds impacting the veterinary sector.

The shift toward double-digit growth indicates that the company's razor-razorblade model is successfully capturing increased diagnostic utilization per visit. Investors should monitor whether this trajectory is sustainable or if it reflects a temporary recovery in clinic foot traffic following previous periods of stagnation.

Structural Gross Margin Resilience Observed

Based on the provided income statement data, IDEXX has maintained gross margins consistently above 60% over the last ten quarters, peaking at 63.4% in 2026Q1, which highlights the company's significant pricing power and the high intellectual property value inherent in its proprietary diagnostic testing ecosystem.

This margin profile suggests that IDEXX is effectively offsetting inflationary pressures in its laboratory network through premium test adoption. The stability of these margins implies that the company's diagnostic menu remains essential to veterinary workflows, insulating it from the commoditization risks faced by lower-tier diagnostic providers.

Operating Leverage Scaling With Efficiency

According to historical quarterly figures, IDEXX has successfully scaled operating income from $245.3 million in 2023Q4 to $362.6 million in 2026Q1, demonstrating that operating expenses are growing at a slower rate than gross profit, thereby expanding the company's overall operating margin profile.

The ability to expand operating margins while continuing to invest in R&D suggests disciplined overhead management and successful integration of software-driven workflows. This trend warrants further investigation into whether future margin expansion will be driven by continued software-as-a-service penetration or further automation within the reference laboratory network.

Earnings Quality Impacted By SBC

Analysis of the income statement reveals that stock-based compensation remains a variable component of the cost structure, with fluctuations such as the $44.1 million credit in 2025Q3, which suggests that reported net income may occasionally be distorted by non-cash accounting adjustments rather than pure operational performance.

While EPS growth has been strong, investors should be cautious of the volatility introduced by these non-operating items when assessing the underlying cash-generating capacity of the business. The absence of consistent SBC charges in recent quarters may indicate a shift in compensation strategy that requires ongoing monitoring.

IDXX — Frequently Asked Questions

Quick answers to the most common questions about buying IDXX stock.

What was IDEXX Laboratories, Inc.'s (IDXX) revenue in 2025?

For fiscal year 2025, IDEXX Laboratories, Inc. (IDXX) reported total revenue of $4.30B. This represents a 1507.7% increase compared to $267.7M in 1996.

Is IDEXX Laboratories, Inc. (IDXX) profitable?

IDEXX Laboratories, Inc. (IDXX) is profitable, generating $1.06B in net income for the fiscal year ending 2025 with a net profit margin of 24.6%.

What is IDEXX Laboratories, Inc.'s operating profit margin?

IDEXX Laboratories, Inc. (IDXX) reported an operating income of $1.36B, resulting in an operating profit margin of 31.6%. This margin reflects the operational efficiency of the business before interest and taxes.

What is IDEXX Laboratories, Inc.'s gross profit and gross margin?

IDEXX Laboratories, Inc. (IDXX) generated $2.66B in gross profit for the year, representing a gross profit margin of 61.8%. This demonstrates the company's core pricing power and production efficiency.